Business Description
Entero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05502L1052
Description
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.49 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 87.9 | |||||
| 3-Year EPS without NRI Growth Rate | 74.9 | |||||
| 3-Year FCF Growth Rate | 84.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.62 | |||||
| 9-Day RSI | 46.16 | |||||
| 14-Day RSI | 42.83 | |||||
| 6-1 Month Momentum % | -51.31 | |||||
| 12-1 Month Momentum % | -94.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 1.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1182.5 | |||||
| Shareholder Yield % | -261.12 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -597.44 | |||||
| ROA % | -280.93 | |||||
| ROIC % | -655.43 | |||||
| ROC (Joel Greenblatt) % | -5522.76 | |||||
| ROCE % | -558.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.23 | |||||
| Price-to-Tangible-Book | 2.32 | |||||
| EV-to-EBIT | -0.2 | |||||
| EV-to-EBITDA | -0.2 | |||||
| EV-to-Forward-Revenue | -64.47 | |||||
| EV-to-FCF | -0.25 | |||||
| Price-to-Net-Current-Asset-Value | 2.66 | |||||
| Price-to-Net-Cash | 10.18 | |||||
| Earnings Yield (Greenblatt) % | -500 | |||||
| FCF Yield % | -214.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENTO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -49.297 | ||
| Beta | 1.32 | ||
| Volatility % | 112.03 | ||
| 14-Day RSI | 42.83 | ||
| 14-Day ATR ($) | 0.298223 | ||
| 20-Day SMA ($) | 2.8215 | ||
| 12-1 Month Momentum % | -94.04 | ||
| 52-Week Range ($) | 2.3335 - 59.998 | ||
| Shares Outstanding (Mil) | 2.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Entero Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Entero Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Entero Therapeutics Inc Frequently Asked Questions
What is Entero Therapeutics Inc(ENTO)'s stock price today?
The current price of ENTO is $2.85. The 52 week high of ENTO is $60.00 and 52 week low is $2.33.
When is next earnings date of Entero Therapeutics Inc(ENTO)?
The next earnings date of Entero Therapeutics Inc(ENTO) is 2024-08-14 Est..
Does Entero Therapeutics Inc(ENTO) pay dividends? If so, how much?
Entero Therapeutics Inc(ENTO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers